Evaluation of clinical and pathological responses of HER-2 positive locally advanced breast cancer patients after neoadjuvant therapy and surgery

Ertuğrul Bayram; Burak Mete; Pakize İrem Kahramanoğlu; Ebru Melekoğlu; Mehmet Turker; İ. Oğuz Kara

Makale detayları

Evaluation of clinical and pathological responses of HER-2 positive locally advanced breast cancer patients after neoadjuvant therapy and surgery

Yazarlar:

Ertuğrul Bayram | Burak Mete | Pakize İrem Kahramanoğlu | Ebru Melekoğlu | Mehmet Turker | İ. Oğuz Kara

Yayıncı:

Cukurova University

Ana Başlıklar:

Cerrahi Onkoloji | Klinik Onkoloji

Dergi:

Cukurova Medical Journal Vol.48 Issue 3, pp.1062-1071

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001286409

pISSN:

2602-3032

Anahtar kelimeler:

Özet:

 Purpose: This study aimed to compare the effectiveness and toxicity of neoadjuvant dual Human epidermal growth factor receptor-2 HER-2 blockade combined with chemotherapy in advanced breast cancer. Materials and Methods: Patients with HER2-positive breast cancer who received trastuzumab T pertuzumab P with weekly neoadjuvant paclitaxel or docetaxel were included in the study. Patients age, clinical stage, histological reports, ki-67 index, toxicity profiles, and the state of the pathological and radiological response following neoadjuvant therapy were evaluated. Results: All 40 patients were women mean age 50.9 and the overall rate of pathological complete responses was 62.5 2540. The rates of non-responsive patients and grade 2 neuropathy were statistically significantly higher in the group receiving PTWeekly Paclitaxel. When SUV values were analyzed based on hormone positivity, it was found that they decreased dramatically in both groups and were statistically significant. The logistic regression analysis developed to predict the precise response status to therapy was found to be significant. Conclusion: When comparing the agents used in dual HER-2 targeted therapies, patient response rates and toxicity profiles may differ. Ductal carcinoma in situ DCIS and molecular subtype were found to be significant variables in the developed logistic regression model.

 Purpose: This study aimed to compare the effectiveness and toxicity of neoadjuvant dual Human epidermal growth factor receptor-2 HER-2 blockade combined with chemotherapy in advanced breast cancer. Materials and Methods: Patients with HER2-positive breast cancer who received trastuzumab T pertuzumab P with weekly neoadjuvant paclitaxel or docetaxel were included in the study. Patients age, clinical stage, histological reports, ki-67 index, toxicity profiles, and the state of the pathological and radiological response following neoadjuvant therapy were evaluated. Results: All 40 patients were women mean age 50.9 and the overall rate of pathological complete responses was 62.5 2540. The rates of non-responsive patients and grade 2 neuropathy were statistically significantly higher in the group receiving PTWeekly Paclitaxel. When SUV values were analyzed based on hormone positivity, it was found that they decreased dramatically in both groups and were statistically significant. The logistic regression analysis developed to predict the precise response status to therapy was found to be significant. Conclusion: When comparing the agents used in dual HER-2 targeted therapies, patient response rates and toxicity profiles may differ. Ductal carcinoma in situ DCIS and molecular subtype were found to be significant variables in the developed logistic regression model.

 Purpose: This study aimed to compare the effectiveness and toxicity of neoadjuvant dual Human epidermal growth factor receptor-2 HER-2 blockade combined with chemotherapy in advanced breast cancer. Materials and Methods: Patients with HER2-positive breast cancer who received trastuzumab T pertuzumab P with weekly neoadjuvant paclitaxel or docetaxel were included in the study. Patients age, clinical stage, histological reports, ki-67 index, toxicity profiles, and the state of the pathological and radiological response following neoadjuvant therapy were evaluated. Results: All 40 patients were women mean age 50.9 and the overall rate of pathological complete responses was 62.5 2540. The rates of non-responsive patients and grade 2 neuropathy were statistically significantly higher in the group receiving PTWeekly Paclitaxel. When SUV values were analyzed based on hormone positivity, it was found that they decreased dramatically in both groups and were statistically significant. The logistic regression analysis developed to predict the precise response status to therapy was found to be significant. Conclusion: When comparing the agents used in dual HER-2 targeted therapies, patient response rates and toxicity profiles may differ. Ductal carcinoma in situ DCIS and molecular subtype were found to be significant variables in the developed logistic regression model.

 Amaç: Bu çalışmanın amacı, ilerlemiş meme kanserinde neoadjuvan dual insan epidermal büyüme faktörü reseptörü 2 HER2 blokajında kullanılan kemoterapotiklerin etkinliğini ve toksisitesini karşılaştırmaktı. Gereç ve Yöntem: Haftalık neoadjuvan paklitaksel veya dosetaksel ile trastuzumab T pertuzumab P alan HER2 pozitif meme kanserli hastalar çalışmaya dahil edildi. Hastaların yaşı, klinik evresi, histolojik raporları, ki-67 indeksi, toksisite profilleri ve neoadjuvan tedavi sonrası patolojik ve radyolojik yanıt durumu değerlendirildi. Bulgular: Çalışmaya dahil edilen 40 hastanın tümü kadındı ortalama yaş 50.9 ve genel patolojik tam yanıt oranı 62.5 idi 2540. Haftalık PTPaklitaksel alan grupta tedaviye yanıtsız hasta ve grade 2 nöropati oranları istatistiksel olarak anlamlı derecede yüksekti. SUV değerleri hormon pozitifliğine göre analiz edildiğinde, her iki grupta da önemli ölçüde azaldığı ve istatistiksel olarak anlamlı olduğu bulundu. Tedaviye kesin yanıt durumunu tahmin etmek için geliştirilen lojistik regresyon analizi anlamlı bulunmuştur. Sonuç: Dual HER-2 hedefli tedavilerde kullanılan ajanlar karşılaştırıldığında hasta yanıt oranları ve toksisite profilleri farklı olabilmektedir. Geliştirilen lojistik regresyon modelinde duktal karsinom in situ DCIS ve moleküler alt tipin anlamlı değişkenler olduğu bulunmuştur.

Makale detayları

Evaluation of clinical and pathological responses of HER-2 positive locally advanced breast cancer patients after neoadjuvant therapy and surgery

Yazarlar:

Ertuğrul Bayram | Burak Mete | Pakize İrem Kahramanoğlu | Ebru Melekoğlu | Mehmet Turker | İ. Oğuz Kara

Yayıncı:

Cukurova University

Ana Başlıklar:

Cerrahi Onkoloji | Klinik Onkoloji

Dergi:

Cukurova Medical Journal Vol.48 Issue 3, pp.1062-1071

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001286409

pISSN:

2602-3032

breast cancer

dual blockage

HER-2

response rate

: Meme kanseri

dual blokaj

HER2

yanıt oranı

Sayı

Makale detayları

Yazarlar: Ertuğrul Bayram | Burak Mete | Pakize İrem Kahramanoğlu | Ebru Melekoğlu | Mehmet Turker | İ. Oğuz Kara

Yayıncı: Cukurova University

Ana Başlıklar: Cerrahi Onkoloji | Klinik Onkoloji

Dergi: Cukurova Medical Journal Vol.48 Issue 3, pp.1062-1071

Belge Tipi: Makale

Yayın Tarihi: 9/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001286409

pISSN: 2602-3032

Sayı

Yazarlar:

Ertuğrul Bayram | Burak Mete | Pakize İrem Kahramanoğlu | Ebru Melekoğlu | Mehmet Turker | İ. Oğuz Kara

Yayıncı:

Cukurova University

Ana Başlıklar:

Cerrahi Onkoloji | Klinik Onkoloji

Dergi:

Cukurova Medical Journal Vol.48 Issue 3, pp.1062-1071

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001286409

pISSN:

2602-3032